Opinion
Video
Treatment Decision-Making Based on the COMMANDS Trials
Author(s):
The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.
- How does the COMMANDS trial and outcomes on erythroid, neutrophil, and platelet lineages impact your treatment decision-making?
- How does the genomic landscape and mutational burden impact clinical outcomes of luspatercept from the COMMANDS trial?
Latest CME
View All
Video
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
online-activity
Video
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Jun 6th 2025 - Jul 12th 2025
online-activity
Video
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Jun 5th 2025 - Jul 12th 2025
online-activity
Related Content
